U.K. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Physiomics

Market Cap: UK£2.7m

Provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland.

Poolbeg Pharma

Market Cap: UK£55.7m

A clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom.

Animalcare Group

Market Cap: UK£231.3m

Develops, sells, and distributes licensed veterinary pharmaceuticals for the companion animal, production animal, and equine veterinary markets in Europe, the Asia-Pacific, and internationally.

IXICO

Market Cap: UK£18.9m

Provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally.

BSF Enterprise

Market Cap: UK£3.8m

Develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong.

hVIVO

Market Cap: UK£58.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America.

Aptamer Group

Market Cap: UK£18.1m

Provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally.

Theracryf

Market Cap: UK£4.8m

A clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders.

Arecor Therapeutics

Market Cap: UK£26.1m

A clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom.

ECO Animal Health Group

Market Cap: UK£62.7m

ECO Animal Health Group plc, together with its subsidiaries, manufactured and supply animal health products internationally.

Diaceutics

Market Cap: UK£121.1m

A diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.

Nuformix

Market Cap: UK£4.4m

Together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.

Bioventix

Market Cap: UK£88.8m

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.

OptiBiotix Health

Market Cap: UK£6.6m

A life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally.

ProBiotix Health

Market Cap: UK£14.2m

Develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally.

Hemogenyx Pharmaceuticals

Market Cap: UK£52.0m

A clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States.

ImmuPharma

Market Cap: UK£28.1m

A biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom.

Genus

Market Cap: UK£1.5b

Produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia.

Fusion Antibodies

Market Cap: UK£15.6m

A contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally.

Oxford Nanopore Technologies

Market Cap: UK£1.3b

Engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA.

4basebio

Market Cap: UK£82.0m

Engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally.

Cardiogeni

Market Cap: UK£6.7m

A clinical stage biotechnology company, develops heart failure medicines.

Oxford BioDynamics

Market Cap: UK£8.2m

Operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom.

Thalia Therapeutics

Market Cap: UK£4.8m

A specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom.

Oxford Biomedica

Market Cap: UK£755.8m

A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

Hikma Pharmaceuticals

Market Cap: UK£3.1b

Develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.

Incanthera

Market Cap: UK£2.6m

A dermatology and oncology therapeutics company, engages in the dermatological formulation and delivery technologies for various indications.

ValiRx

Market Cap: UK£1.4m

A biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom.

CRISM Therapeutics

Market Cap: UK£6.0m

Develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs.

Futura Medical

Market Cap: UK£3.5m

Research, develops, and commercializes pharmaceutical and healthcare products for sexual health.

Palatin Technologies

Market Cap: US$24.2m

A biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.

Sareum Holdings

Market Cap: UK£32.6m

A clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases.

Avacta Group

Market Cap: UK£319.6m

Engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally.

Solvonis Therapeutics

Market Cap: UK£15.2m

A clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders.